This ARWR PE ratio history page last updated 3/11/2024
Period | Price | GAAP | TTM | PE |
Q1 2024 2/6/2024 | 33.20 | -1.24 | -2.77 | NA | Q4 2023 11/29/2023 | 28.98 | -1.02 | -1.92 | NA | Q3 2023 8/7/2023 | 30.81 | -0.96 | -1.71 | NA | Q2 2023 5/2/2023 | 35.38 | 0.45 | -1.43 | NA | Q1 2023 2/6/2023 | 33.51 | -0.39 | -1.47 | NA | Q4 2022 11/28/2022 | 28.00 | -0.81 | -1.68 | NA | Q3 2022 8/4/2022 | 46.13 | -0.68 | -1.48 | NA | Q2 2022 5/10/2022 | 34.29 | 0.41 | -1.09 | NA | Q1 2022 2/2/2022 | 52.63 | -0.60 | -1.76 | NA | Q4 2021 11/22/2021 | 69.28 | -0.61 | -1.36 | NA | Q3 2021 8/5/2021 | 68.05 | -0.29 | -1.23 | NA | Q2 2021 5/4/2021 | 66.48 | -0.26 | -1.07 | NA | Q1 2021 2/4/2021 | 83.92 | -0.20 | -1.01 | NA | Q4 2020 11/23/2020 | 68.20 | -0.48 | -0.84 | NA | Q3 2020 8/5/2020 | 43.56 | -0.13 | -0.25 | NA | Q2 2020 5/7/2020 | 35.13 | -0.20 | 0.09 | 390.3 | Q1 2020 2/5/2020 | 43.72 | -0.03 | 0.53 | 82.5 | Q4 2019 11/25/2019 | 56.99 | 0.11 | 0.69 | 82.6 | Q3 2019 8/5/2019 | 27.24 | 0.21 | 0.46 | 59.2 | Q2 2019 5/8/2019 | 18.33 | 0.24 | 0.07 | 261.9 | Q1 2019 2/7/2019 | 13.30 | 0.13 | -0.35 | NA | Q4 2018 12/11/2018 | 13.62 | -0.12 | -0.66 | NA | Q3 2018 8/7/2018 | 15.10 | -0.18 | -0.69 | NA | Q2 2018 5/8/2018 | 7.75 | -0.18 | -0.58 | NA | Q1 2018 2/9/2018 | 5.59 | -0.18 | -0.48 | NA | Q4 2017 12/12/2017 | 3.55 | -0.15 | -0.47 | NA | Q3 2017 8/3/2017 | 1.70 | -0.07 | -0.66 | NA | Q2 2017 5/3/2017 | 1.56 | -0.08 | -0.91 | NA | Q1 2017 2/6/2017 | 1.88 | -0.17 | -1.18 | NA | Q4 2016 12/14/2016 | 1.27 | -0.34 | -1.33 | NA | Q3 2016 8/9/2016 | 6.39 | -0.32 | -1.40 | NA | Q2 2016 5/10/2016 | 5.72 | -0.35 | -1.35 | NA | Q1 2016 2/9/2016 | 3.18 | -0.32 | -1.51 | NA | Q4 2015 12/14/2015 | 5.69 | -0.41 | -1.60 | NA | Q3 2015 8/4/2015 | 6.03 | -0.27 | -1.61 | NA | Q2 2015 5/11/2015 | 6.69 | -0.51 | -1.56 | NA | Q1 2015 2/9/2015 | 6.21 | -0.41 | -0.74 | NA | Q4 2014 11/25/2014 | 5.84 | -0.42 | -0.05 | NA | Q3 2014 8/12/2014 | 13.00 | -0.22 | -0.93 | NA | Q2 2014 5/6/2014 | 10.22 | 0.31 | -0.94 | NA | Q1 2014 4/4/2014 | 16.21 | 0.28 | -1.66 | NA | FY 2013 12/18/2013 | 9.14 | -1.30 | -2.22 | NA | Q3 2013 8/7/2013 | 4.34 | -0.23 | -1.35 | NA | Q2 2013 5/9/2013 | 2.01 | -0.41 | NA | NA | Q1 2013 2/4/2013 | 1.94 | -0.28 | NA | NA | Q4 2012 12/20/2012 | 2.11 | -0.43 | NA | NA |
|
Period | Price | GAAP | Annualized | PE |
Q1 2024 2/6/2024 | 33.20 | -1.24 | -4.96 | NA | Q4 2023 11/29/2023 | 28.98 | -1.02 | -4.08 | NA | Q3 2023 8/7/2023 | 30.81 | -0.96 | -3.84 | NA | Q2 2023 5/2/2023 | 35.38 | 0.45 | 1.80 | 19.7 | Q1 2023 2/6/2023 | 33.51 | -0.39 | -1.56 | NA | Q4 2022 11/28/2022 | 28.00 | -0.81 | -3.24 | NA | Q3 2022 8/4/2022 | 46.13 | -0.68 | -2.72 | NA | Q2 2022 5/10/2022 | 34.29 | 0.41 | 1.64 | 20.9 | Q1 2022 2/2/2022 | 52.63 | -0.60 | -2.40 | NA | Q4 2021 11/22/2021 | 69.28 | -0.61 | -2.44 | NA | Q3 2021 8/5/2021 | 68.05 | -0.29 | -1.16 | NA | Q2 2021 5/4/2021 | 66.48 | -0.26 | -1.04 | NA | Q1 2021 2/4/2021 | 83.92 | -0.20 | -0.80 | NA | Q4 2020 11/23/2020 | 68.20 | -0.48 | -1.92 | NA | Q3 2020 8/5/2020 | 43.56 | -0.13 | -0.52 | NA | Q2 2020 5/7/2020 | 35.13 | -0.20 | -0.80 | NA | Q1 2020 2/5/2020 | 43.72 | -0.03 | -0.12 | NA | Q4 2019 11/25/2019 | 56.99 | 0.11 | 0.44 | 129.5 | Q3 2019 8/5/2019 | 27.24 | 0.21 | 0.84 | 32.4 | Q2 2019 5/8/2019 | 18.33 | 0.24 | 0.96 | 19.1 | Q1 2019 2/7/2019 | 13.30 | 0.13 | 0.52 | 25.6 | Q4 2018 12/11/2018 | 13.62 | -0.12 | -0.48 | NA | Q3 2018 8/7/2018 | 15.10 | -0.18 | -0.72 | NA | Q2 2018 5/8/2018 | 7.75 | -0.18 | -0.72 | NA | Q1 2018 2/9/2018 | 5.59 | -0.18 | -0.72 | NA | Q4 2017 12/12/2017 | 3.55 | -0.15 | -0.60 | NA | Q3 2017 8/3/2017 | 1.70 | -0.07 | -0.28 | NA | Q2 2017 5/3/2017 | 1.56 | -0.08 | -0.32 | NA | Q1 2017 2/6/2017 | 1.88 | -0.17 | -0.68 | NA | Q4 2016 12/14/2016 | 1.27 | -0.34 | -1.36 | NA | Q3 2016 8/9/2016 | 6.39 | -0.32 | -1.28 | NA | Q2 2016 5/10/2016 | 5.72 | -0.35 | -1.40 | NA | Q1 2016 2/9/2016 | 3.18 | -0.32 | -1.28 | NA | Q4 2015 12/14/2015 | 5.69 | -0.41 | -1.64 | NA | Q3 2015 8/4/2015 | 6.03 | -0.27 | -1.08 | NA | Q2 2015 5/11/2015 | 6.69 | -0.51 | -2.04 | NA | Q1 2015 2/9/2015 | 6.21 | -0.41 | -1.64 | NA | Q4 2014 11/25/2014 | 5.84 | -0.42 | -1.68 | NA | Q3 2014 8/12/2014 | 13.00 | -0.22 | -0.88 | NA | Q2 2014 5/6/2014 | 10.22 | 0.31 | 1.24 | 8.2 | Q1 2014 4/4/2014 | 16.21 | 0.28 | 1.12 | 14.5 | FY 2013 12/18/2013 | 9.14 | -1.30 | -5.20 | NA | Q3 2013 8/7/2013 | 4.34 | -0.23 | -0.92 | NA | Q2 2013 5/9/2013 | 2.01 | -0.41 | -1.64 | NA | Q1 2013 2/4/2013 | 1.94 | -0.28 | -1.12 | NA | Q4 2012 12/20/2012 | 2.11 | -0.43 | -1.72 | NA |
|
On this page we presented the ARWR PE Ratio History information for Arrowhead Pharma' stock.
The average ARWR PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 33.7. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ARWR PE ratio history based on this TTM earnings result method is 175.3. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this ARWR PE ratio history result, against the recent PE: when this page was posted on 3/8/2024, the most recent closing price for ARWR had been 33.45, and the most recent quarterly earnings result, annualized, was 1.8. Meanwhile, the most recent TTM earnings summed to 0.09. From these numbers, we calculate the recent ARWR PE on 3/8/2024 based on annualized quarterly EPS was 18.6. Based on ARWR's history, that recent PE is low relative to the historical average, with the recent PE 44.8% lower than the historical average PE across our data set for Arrowhead Pharma. Looking at the recent ARWR PE on 3/8/2024 based on TTM EPS, we calculate the ratio at 371.7. Based on ARWR's history, that recent PE is elevated relative to the historical average, with the recent PE 112.0% higher than the historical average PE across our Arrowhead Pharma data set with TTM EPS used in the calculation at each period.
For self directed investors doing their due diligence on ARWR or any other given stock, valuation analysis for ARWR
can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can
help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios
justify the current stock market value.
That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate
Arrowhead Pharma PE ratio history — or the PE history for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for
next earnings dates and also historical earnings surprises history for ARWR. Thanks for visiting, and the next
time you need to research ARWR PE Ratio History or the PE ratio history for another stock, we hope our site
will come to mind as your go-to PE ratio history research resource of choice.